Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12O3 |
| Molecular Weight | 228.2433 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
InChI
InChIKey=LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
| Molecular Formula | C14H12O3 |
| Molecular Weight | 228.2433 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Resveratrol, a natural non-flavonoid polyphenol, exhibits a wide range of beneficial properties as an anticancer agent, a platelet anti-aggregation agent, and an antioxidant, as well as its anti-aging, anti-inflammatory, antiallergenic. This compound is in phase III clinical trials in combination with carboxymethyl-β-glucan for improving nasal symptoms in children with pollen-induced allergic rhinitis. Also in phase III clinical trial in the treatment of painful knee osteoarthritis and in type 2 diabetic patients. It has been demonstrated that resveratrol may prevent type 2 diabetic by targeting Sirtuin type 1 (SIRT1), indicating that SIRT1 may be a novel therapeutic target for diabetes prevention.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q96EB6 Gene ID: 23411.0 Gene Symbol: SIRT1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1274 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
689 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
1272 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1296 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3558 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1966 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
4025 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20528005/ |
2000 mg 2 times / day multiple, oral dose: 2000 mg route of administration: Oral experiment type: MULTIPLE co-administered: QUERCETIN |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224342/ |
RESVERATROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
Disc. AE: Abnormal liver function tests... Other AEs: Upper respiratory tract infection NOS, Urinary tract infection NOS... AEs leading to discontinuation/dose reduction: Abnormal liver function tests (7%) Other AEs:Upper respiratory tract infection NOS (36%) Sources: Urinary tract infection NOS (7%) Headache (21%) Fatigue (14%) Loose stools (86%) Diarrhea (grade 1-3, 71%) Abdominal pain (71%) Nausea (36%) Bloating (7%) Flatulence (13%) Constipation (7%) Dyspepsia (7%) creatine kinase (14%) Microalbuminuria (21%) Skin rash (29%) Edema lower limb (7%) |
5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Abdominal pain, Diarrhea... Other AEs: Abdominal pain (grade 1, 30%) Sources: Diarrhea (grade 1-3, 70%) Flatulence (grade 1, 20%) Nausea (grade 1, 30%) Chest pain (grade 1, 10%) Dizziness (grade 1, 10%) Dry mouth (grade 1, 10%) Red eye (grade 1, 10%) Urine color abnormal (grade 1, 10%) |
5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Albumin increased, Blood phosphate increased... Other AEs: Albumin increased (grade 1, 10%) Sources: Blood phosphate increased (grade 1, 20%) Glucose increased (grade 1, 10%) Carbon dioxide low (grade 1, 20%) Lactate dehydrogenase increased (grade 1, 10%) Blood lactate dehydrogenase decreased (grade 1, 10%) Eosinophil count increased (grade 1, 10%) Chloride increased (grade 1, 10%) |
1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
Disc. AE: Skin rash, Constipation... Other AEs: Diarrhea, Allergic reaction... AEs leading to discontinuation/dose reduction: Skin rash (grade 3, 6%) Other AEs:Constipation (grade 2, 3%) Diarrhea (grade 2, 6%) Sources: Allergic reaction (grade 2, 3%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Flatulence | 13% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Fatigue | 14% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| creatine kinase | 14% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Headache | 21% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Microalbuminuria | 21% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Skin rash | 29% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Nausea | 36% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Upper respiratory tract infection NOS | 36% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Bloating | 7% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Constipation | 7% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Dyspepsia | 7% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Edema lower limb | 7% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Urinary tract infection NOS | 7% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Abnormal liver function tests | 7% Disc. AE |
5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Abdominal pain | 71% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Loose stools | 86% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Diarrhea | grade 1-3, 71% | 5 g 2 times / day multiple, oral Highest studied dose Dose: 5 g, 2 times / day Route: oral Route: multiple Dose: 5 g, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: LOW-FAT Sources: |
| Chest pain | grade 1, 10% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | grade 1, 10% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dry mouth | grade 1, 10% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Red eye | grade 1, 10% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Urine color abnormal | grade 1, 10% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Flatulence | grade 1, 20% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Abdominal pain | grade 1, 30% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | grade 1, 30% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhea | grade 1-3, 70% | 5 g 1 times / day multiple, oral Highest studied dose Dose: 5 g, 1 times / day Route: oral Route: multiple Dose: 5 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Albumin increased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Blood lactate dehydrogenase decreased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Chloride increased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Eosinophil count increased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Glucose increased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Lactate dehydrogenase increased | grade 1, 10% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Blood phosphate increased | grade 1, 20% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Carbon dioxide low | grade 1, 20% | 5 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Allergic reaction | grade 2, 3% | 1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
| Constipation | grade 2, 3% Disc. AE |
1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
| Diarrhea | grade 2, 6% | 1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
| Skin rash | grade 3, 6% Disc. AE |
1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [IC50 >50 uM] | ||||
| no [IC50 >50 uM] | ||||
| no [IC50 >50 uM] | ||||
| no [IC50 >50 uM] | ||||
| no [IC50 >50 uM] | ||||
| no [IC50 >50 uM] | ||||
| weak [IC50 11.6 uM] | ||||
| weak [IC50 150 uM] | ||||
| weak [IC50 34.8 uM] | ||||
| weak [IC50 35.2 uM] | ||||
| weak [IC50 40 uM] | ||||
| weak [IC50 >25 uM] | ||||
| weak [IC50 >50 uM] | ||||
| weak | weak (biomarker study) Comment: A weak induction of CYP1A2 was shown in vivo after 4 weeks of 1 g of resveratrol per day in healthy volunteers by measuring the ratio between caffeine and the metabo-lite, paraxanthine. |
|||
| yes [IC50 1.4 uM] | ||||
| yes [IC50 11.6 uM] | ||||
| yes [IC50 2.3 uM] | yes (biomarker study) Comment: Resveratrol ingestion of 1 g per day for 4 weeks decreased human CYP2C9 activity. |
|||
| yes [IC50 8.3 uM] | ||||
| yes [IC50 9.1 uM] | ||||
| yes [IC50 9.57 uM] | ||||
| yes [IC50 9.8 uM] | yes (biomarker study) Comment: Data in humans showed a decrease of CYP2D6 activity after 4 weeks of 1 g of resveratrol per day |
|||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| minor [Km <=58 uM] | ||||
| no | ||||
| weak | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. | 1998 Dec 11 |
|
| Cancer chemopreventive activity of resveratrol. | 1999 |
|
| Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. | 1999 Apr 15 |
|
| Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. | 1999 Aug |
|
| Resveratrol is a selective human cytochrome P450 1A1 inhibitor. | 1999 Aug 19 |
|
| Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. | 1999 Feb |
|
| Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. | 1999 May 14 |
|
| Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. | 1999 Nov 26 |
|
| Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. | 1999 Oct |
|
| Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. | 1999 Oct |
|
| Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. | 1999 Oct 1 |
|
| 24R,25-(OH)(2)D(3) mediates its membrane receptor-dependent effects on protein kinase C and alkaline phosphatase via phospholipase A(2) and cyclooxygenase-1 but not cyclooxygenase-2 in growth plate chondrocytes. | 2000 Mar |
|
| Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. | 2000 Oct |
|
| Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. | 2000 Oct |
|
| Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia. | 2000 Oct |
|
| Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2). | 2001 |
|
| Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. | 2001 Apr 1 |
|
| The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human cyp1a1 expression. | 2001 Aug |
|
| Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. | 2001 Feb 15 |
|
| Do wine polyphenols modulate p53 gene expression in human cancer cell lines? | 2001 Jul |
|
| Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. | 2001 Jul |
|
| Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. | 2001 Jun |
|
| Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. | 2001 Jun 1 |
|
| Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT). | 2001 Jun 1 |
|
| Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. | 2001 Jun 15 |
|
| Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. | 2001 Mar |
|
| Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. | 2001 Nov |
|
| Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. | 2002 Jun |
|
| Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. | 2002 Mar 1 |
|
| Flavonoid effects relevant to cancer. | 2002 Nov |
|
| Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. | 2002 Oct 11 |
|
| Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. | 2003 Apr |
|
| Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. | 2003 Apr 1 |
|
| Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens. | 2003 Apr 30 |
|
| Resveratrol induces apoptosis in human esophageal carcinoma cells. | 2003 Mar |
|
| Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. | 2003 Mar |
|
| Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. | 2003 May |
Patents
Sample Use Guides
Seasonal Allergic Rhinitis: 2 sprays per nostril 3 times a day for a period of two months
knee osteoarthritis: resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
Route of Administration:
Other
The insulinoma cell line clone 1E (INS-1E) was treated with palmitic acid (PA). PA suppressed the expression of SIRT1 in a dose- and time-dependent manner. In PA-induced INS-1E cells, it was demonstrated that 10 µM resveratrol modulated the expression of PGC-1α and FOXO3a via SIRT1 and regulated the expression of mitochondrial biogenesis-associated, lipid metabolism-associated and β-cells-associated proteins.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:00 GMT 2025
by
admin
on
Mon Mar 31 18:27:00 GMT 2025
|
| Record UNII |
Q369O8926L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/16/1827
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
||
|
DSLD |
438 (Number of products:1077)
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
||
|
FDA ORPHAN DRUG |
597817
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
||
|
NCI_THESAURUS |
C54630
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
||
|
FDA ORPHAN DRUG |
241707
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1602105
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
224
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
Resveratrol
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
445154
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
327430
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
SUB32889
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
DTXSID4031980
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
C1215
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
45713
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
501-36-0
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
7571
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
1000492
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
C059514
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
100000126143
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
Q369O8926L
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
DB02709
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
RESVERATROL
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
Q369O8926L
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | |||
|
m9549
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
27881
Created by
admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Representative of PDE4
|
||
|
TRANSPORTER -> INHIBITOR |
inhibited MTX efflux transport in MDR1-MDCK and MRP2-MDCK cellmonolayers, suggesting that the target of drug interaction wasMDR1 andMRP2 in the intestine duringthe absorption process.
|
||
|
TRANSPORTER -> INHIBITOR |
inhibited MTX efflux transport in MDR1-MDCK and MRP2-MDCK cellmonolayers, suggesting that the target of drug interaction wasMDR1 andMRP2 in the intestine duringthe absorption process.
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Stilbene was determined by means of of a newly developed rapid, sensitive, and accurate HPLC-DAD method.
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ACTIVE CONSTITUENT ALWAYS PRESENT |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
6?-hydroxylation of testosterone
IC50
|
||
|
TARGET -> ACTIVATOR |
Resveratrol activates deacetylase activity while inhibiting desuccinylase activity.
|
||
|
TRANSPORTER -> INHIBITOR |
MTX uptake was markedly inhibited by Res in rat kidney slicesand hOAT1/3-HEK293 cell, indicating that OAT1 and OAT3 were involved in the drug interaction in the kidney
|
||
|
TRANSPORTER -> INHIBITOR |
MTX uptake was markedly inhibited by Res in rat kidney slicesand hOAT1/3-HEK293 cell, indicating that OAT1 and OAT3 were involved in the drug interaction in the kidney
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
CONSTITUENT ALWAYS PRESENT -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR |
resveratrol inactivated CYP3A4 in a time- and NADPH-dependent manner, with rate (kinact) and affinity (equilibrium dissociation constant for enzyme-inhibitor complex; KI) of 0.2?min?1 and 20 ?M, respectively
TIME-DEPENDENT INHIBITION
Ki
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Activity against BACE-1 with Ki value of 5.4 x 10-6M and IC50 of 1.5 x 10-5M.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
Some patients formed this metabolite presumably due to microbiome differences.
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
